Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Thymic aplasia 1Immunologic Deficiency Syndromes 1

Interventions

Saline Solution 10Docetaxel 10Bevacizumab 9nilotinib 8enzalutamide 8Paclitaxel 8Letrozole 8Fentanyl 8Everolimus 8Cyclophosphamide 8Carboplatin 8Bupivacaine 8Lidocaine 7Sodium Chloride 6Oxycodone 6Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 6Erlotinib Hydrochloride 6Dexamethasone 6Capecitabine 6Trastuzumab 5Tobacco Use Cessation Devices 5Surveys and Questionnaires 5Nivolumab 5Hydromorphone 5Adalimumab 5fludarabine 4Zoledronic Acid 4Tranexamic Acid 4Tacrolimus 4Rocuronium 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Has results × Phlebotomy × Clear all
NCT02274662 2025-01-16

Expanded Access Protocol Thymus Transplantation

Sumitomo Pharma Switzerland GmbH

Phase 4 Completed
11 enrolled 10 charts

Thymic aplasia, Immunologic Deficiency Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡